Author

Frank Hoentjen 1

1 Radboud University Medical Center,Nijmegen,Netherlands

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

Reinier C. A. van Linschoten, Fenna Minke Jansen, Renske W. M. Pauwels, Lisa J. T. Smits, Femke Atsma, Wietske Kievit, Paul Boekema, Rachel West, Alexander G. L. Bodelier, Ingrid A. M. Gisbertz, Frank H. J. Wolfhagen, Tessa E. H. Römkens, Maurice W. M. D. Lutgens, Adriaan A. Van Bodegraven, Bas Oldenburg, Marieke Pierik, Ma

COLORECTAL CANCER RISK IN A NATIONWIDE INFLAMMATORY BOWEL DISEASE COHORT WITH LOW GRADE DYSPLASIA

Lauranne Derikx, Sanne van Tilburg, Iris D. Nagtegaal, Loes Nissen, Frank Hoentjen

COLORECTAL CANCER RISK IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH HIGH-GRADE DYSPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Maarten te Groen, Kirsten Peters, Frank Hoentjen, Lauranne A.A.P. Derikx

COLORECTAL CANCER RISK IN PATIENTS WITH BOTH LYNCH SYNDROME AND INFLAMMATORY BOWEL DISEASE

Lauranne A.A.P. Derikx, Lisa J.T. Smits, Evelien Dekker, Cora M. Aalfs, Fokko M. Nagengast, Nicoline Hoogerbrugge, Frank Hoentjen

Combined endoscopic and histological healing with vedolizumab in therapy-refractory Crohn's disease, data from the LOVE-CD trial

Mark Lowenberg, Nahid Mostafavi, Severine Vermeire, Frank Hoentjen, C. Ambarus, Esmé Clasquin, Filip Baert, Geert R. D'Haens

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Fenna Minke Jansen, Reinier C. A. van Linschoten, Renske Wilhelmina Maria Pauwels, Lisa S. Smits, Wietske Kievit, Paul Boekema, Rachel West, Alexander G. L. Bodelier, Ingrid A. M. Gisbertz, Frank H. J. Wolfhagen, Tessa E.H. Römkens, Maurice W. M. D. Lutgens, Adriaan A. Van Bodegraven, Bas Oldenburg, Marieke Pierik, Maurice G

DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION

Maurice Russel, Pepijn Thomas, Maarten te Groen, Rachel West, Lisa S. Smits, Jeroen Michiel Jansen, Frank Hoentjen, Tessa E.H. Römkens

DEVELOPMENT AND FEASIBILITY OF A WEB-BASED REGISTRY FOR MULTICENTRE SURVEILLANCE OF EFFECTIVENESS AND SAFETY OF NOVEL IBD-DRUGS IN THE NETHERLANDS

Vince B.C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. Van Der Meulen - De Jong, K.H.N. (Nanne) de Boer, Cyriel Y. Ponsioen, Bas Oldenburg, Frank Hoentjen, Marieke J. Pierik

HIGHER EARLY VEDOLIZUMAB CONCENTRATIONS AT TROUGH ARE ASSOCIATED WITH ENDOSCOPIC REMISSION AT 26 WEEKS IN CROHN’S DISEASE

Mark Lowenberg, Sophie Berends, Severine Vermeire, Ron Mathôt, Esmé Clasquin, Frank Hoentjen, Peter Bossuyt, Philippe Van Hootegem, Martine De Vos, Geert R. D'Haens, Filip Baert

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Geert R. D'Haens, Peter Bossuyt, Filip Baert, Tamás Molnár, Wouter Van Moerkercke, Esmee Clasquin, Mark Lowenberg, Nahid Mostafavi, Harald Peeters, Guy Lambrecht, Frank Hoentjen, Severine Vermeire

Item 1 - 10 / 27
1
2 3